Results 231 to 240 of about 43,637 (267)

Functional Gene Variants of CYP3A4

Clinical Pharmacology & Therapeutics, 2014
Cytochrome P450 3A4 (CYP3A4) is involved in the metabolism of more drugs in clinical use than any other foreign compound-metabolizing enzyme in humans. Recently, increasing evidence has been found showing that variants in the CYP3A4 gene have functional significance and--in rare cases--lead to loss of activity, implying tremendous consequences for ...
A N, Werk, I, Cascorbi
openaire   +2 more sources

Human variability in CYP3A4 metabolism and CYP3A4-related uncertainty factors for risk assessment

Food and Chemical Toxicology, 2003
CYP3A4 constitutes the major liver cytochrome P450 isoenzyme and is responsible for the oxidation of more than 50% of all known drugs. Human variability in kinetics for this pathway has been quantified using a database of 15 compounds metabolised extensively (>60%) by this CYP isoform in order to develop CYP3A4-related uncertainty factors for the risk ...
Dorne, J.L.C.M., Walton, K., Renwick, A.G.   +2 more
openaire   +3 more sources

CYP3A4*16 and CYP3A4*18 Alleles Found in East Asians Exhibit Differential Catalytic Activities for Seven CYP3A4 Substrate Drugs

Drug Metabolism and Disposition, 2010
CYP3A4, the major form of cytochrome P450 (P450) expressed in the adult human liver, is involved in the metabolism of approximately 50% of commonly prescribed drugs. Several genetic polymorphisms in CYP3A4 are known to affect its catalytic activity and to contribute in part to interindividual differences in the pharmacokinetics and pharmacodynamics of ...
Keiko, Maekawa, Noriko, Harakawa, Takuya, Yoshimura, Su-Ryang, Kim, Yoshiyuki, Fujimura, Fumika, Aohara, Kimie, Sai, Noriko, Katori, Masahiro, Tohkin, Mikihiko, Naito, Ryuichi, Hasegawa, Haruhiro, Okuda, Jun-ichi, Sawada, Takuro, Niwa, Yoshiro, Saito   +14 more
openaire   +2 more sources

CYP3A4 variant alleles in white individuals with low CYP3A4 enzyme activity

Clinical Pharmacology & Therapeutics, 2002
ObjectiveOur objective was to evaluate the presence of CYP3A4 gene variants in white individualswith low CYP3A4 enzyme activity.MethodsPersons with extremely low enzyme activity, either in vitro or in vivo, were selected in a panel of 97 healthy subjects. Genetic analyses for CYP3A4 variant alleles present in white subjects, including CYP3A4*1B, CYP3A4*
Elena, García-Martín, Carmen, Martínez, Rosa M, Pizarro, Francisco J, García-Gamito, Harriet, Gullsten, Hannu, Raunio, José A G, Agúndez   +6 more
openaire   +2 more sources

Utility of CYP3A4 and PXR-CAR-CYP3A4/3A7 Transgenic Mouse Models To Assess the Magnitude of CYP3A4 Mediated Drug–Drug Interactions

Molecular Pharmaceutics, 2017
Species differences in the expression, activity, regulation, and substrate specificity of metabolizing enzymes preclude the use of animal models to predict clinical drug-drug interactions (DDIs). The objective of this work is to determine if the transgenic (Tg) Cyp3a-/-Tg-3A4Hep/Int and Nr1i2/Nr1i3-/--Cyp3a-/-Tg-PXR-CAR-3A4/3A7Hep/Int (PXR-CAR-CYP3A4 ...
Justin Q. Ly, Kirsten Messick, Ann Qin, Ryan H. Takahashi, Edna F. Choo   +4 more
openaire   +2 more sources

Lessons from the CYP3A4 Promoter

Molecular Pharmacology, 2004
There is considerable interest in determining the molecular basis for human variation in drug response. Investigations over the past 20 years have largely focused on identifying polymorphisms in genes that encode drug metabolism enzymes.
openaire   +2 more sources

CYP3A4*22: Promising Newly IdentifiedCYP3A4Variant Allele for Personalizing Pharmacotherapy

Pharmacogenomics, 2012
Many studies have attempted to explain the interindividual variability observed in drug metabolism by assessing the impact of SNPs in genes implicated in drug absorption, distribution, metabolism and excretion pathways. Particular attention has been paid to the CYP450s.
Elens, Laure, Gelder, Teun, Hesselink, Dennis, Haufroid, V, van Schaik, Ron   +4 more
openaire   +3 more sources

Transport and Metabolic Characterization of Caco-2 Cells Expressing CYP3A4 and CYP3A4 Plus Oxidoreductase

Pharmaceutical Research, 1999
To further characterize CYP3A4-transfected Caco-2 cells with regard to morphological, transport, and metabolic properties, and to evaluate a different Caco-2 cell strain transfected with both CYP3A4 and oxidoreductase (OR).Transfected Caco-2 cells, Caco-2 TC7 cells, and wild-type Caco-2 cells grown onto Millicell were used.
M, Hu, Y, Li, C M, Davitt, S M, Huang, K, Thummel, B W, Penman, C L, Crespi   +6 more
openaire   +2 more sources

Identification and characterization of CYP3A4*20, a novel rare CYP3A4 allele without functional activity

Clinical Pharmacology & Therapeutics, 2006
The major drug-metabolizing enzyme cytochrome P450 (CYP) 3A4 is genetically conserved. One outlier of Brazilian descent was found in a clinical pharmacokinetic trial exhibiting a 6-fold higher exposure than expected to an investigational drug, shown to be a CYP3A4 substrate.
Anna, Westlind-Johnsson, Robert, Hermann, Andreas, Huennemeyer, Bernhard, Hauns, Gezim, Lahu, Nassr, Nassr, Karl, Zech, Magnus, Ingelman-Sundberg, Oliver, von Richter   +8 more
openaire   +2 more sources

Genetic polymorphisms of CYP3A4: CYP3A4⁎18 allele is found in five healthy Malaysian subjects

Clinica Chimica Acta, 2007
Cytochrome P450 3A4 (CYP3A4) is the major cytochrome involved in metabolizing of >60% of all drugs used in humans. A number of allelic variations in CYP3A4 gene are known to affect catalytic activity including CYP3A4*4, CYP3A4*5 and CYP3A4*18. We investigated the frequencies of CYP3A4*4, CYP3A4*5 and CYP3A4*18 alleles in a Malaysian population.
A B, Ruzilawati, A W Mohd, Suhaimi, S H, Gan   +2 more
openaire   +2 more sources